ENDPOINTS NEWS12h
Bi­par­ti­san 'pill penal­ty' fix and oth­er bills vie for in­clu­sion in rec­on­cil­i­a­tion pack­age
Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...
ENDPOINTS NEWS16h
Prax­is says its es­sen­tial tremor drug failed a Phase 3 read­out but plans to com­plete study
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...
ENDPOINTS NEWS14h
CHMP rec­om­mends Re­gen­eron, No­var­tis drugs that still await FDA ap­proval
CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...
ENDPOINTS NEWS19h
Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen
BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...
ENDPOINTS NEWS15h
In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el
Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up ...
ENDPOINTS NEWS20h
Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves
William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...